Related Experiment Video
Updated: Sep 10, 2025
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
Clinical Significance of Adropin and Salusins Circulating Levels in End-Stage Kidney Disease Patients With
Fatma E S Lashin1, Fatma F Abdel Hamid1, Amr D M El-Guindy2
1Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Insights
Adropin deficiency and altered salusin levels (Sal-β/Sal-α ratio) are linked to cardiovascular disease (CVD) in end-stage kidney disease (ESKD) patients. These biomarkers aid in diagnosing CVD in this high-risk group.
Area of Science:
- Nephrology
- Cardiology
- Biomarker Discovery
Background:
- End-stage kidney disease (ESKD) patients have a high risk of cardiovascular disease (CVD).
- Early detection of CVD complications is crucial for managing ESKD patients.
- This study investigates novel biomarkers for CVD in ESKD.
Purpose of the Study:
- To evaluate the clinical utility of adropin, salusin-α (Sal-α), and salusin-β (Sal-β) in ESKD patients.
- To determine if these biomarkers can differentiate ESKD patients with CVD from those without.
Main Methods:
- Recruited 149 participants: healthy controls (n=50), ESKD without CVD (n=50), and ESKD with CVD (n=49).
- Measured anthropometric data, kidney and cardiac function markers.
- Quantified circulating levels of adropin, Sal-α, and Sal-β.
Main Results:
- ESKD patients with CVD had lower adropin and Sal-α levels.
- Elevated Sal-β levels and a higher Sal-β/Sal-α ratio were observed in ESKD patients with CVD.
- Adropin, Sal-β, and the Sal-β/Sal-α ratio showed diagnostic potential for CVD in ESKD.
Conclusions:
- Adropin insufficiency and salusin imbalance may contribute to CVD pathogenesis in ESKD.
- Circulating adropin, Sal-β, and the Sal-β/Sal-α ratio are promising biomarkers for CVD in ESKD.
- These biomarkers can aid in the diagnosis and management of CVD in high-risk ESKD populations.
Introduction:
Patients with end-stage kidney disease (ESKD) face a significantly increased risk of cardiovascular disease (CVD). Effective management of these patients necessitates the early identification and continuous monitoring of cardiovascular complications. This study aimed to evaluate the clinical utility of circulating adropin, salusin-α (Sal-α), and salusin-β (Sal-β) levels in ESKD patients, with and without co-occurring CVD.
Methods:
We enrolled 149 participants, categorized into three groups: healthy controls (n = 50), ESKD patients without CVD (n = 50), and ESKD patients with CVD (n = 49). We measured anthropometric parameters, markers of kidney and cardiac function, and circulating levels of adropin, Sal-α, and Sal-β.
Results:
Serum adropin and Sal-α levels were significantly lower in ESKD patients with CVD compared to both healthy controls and ESKD patients without CVD. Conversely, ESKD patients with CVD exhibited significantly higher Sal-β levels and a higher Sal-β/Sal-α ratio when compared to controls and ESKD patients without CVD. Furthermore, high circulating adropin levels were associated with a decreased risk of CVD, whereas elevated circulating Sal-β levels and an increased Sal-β/Sal-α ratio were associated with an increased CVD risk. The Sal-β level and Sal-β/Sal-α ratio demonstrated the highest diagnostic efficacy in differentiating ESKD patients with CVD from those without CVD. Combining these parameters further improved diagnostic efficacy.
Conclusion:
Adropin insufficiency and an imbalance in salusin levels (specifically an elevated Sal-β/Sal-α ratio) may play a role in the pathogenesis of CVD in ESKD patients. The circulating levels of adropin and Sal-β, along with the Sal-β/Sal-α ratio, appear to be valuable diagnostic biomarkers for CVD in this high-risk population.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:22Heart Failure Drugs: Diuretics
01:20Acute Kidney Injury V: Interprofessional Care
01:26Nephrotic Syndrome II : Assessment and Medical Management